Mai Capital Management Galecto, Inc. Transaction History

Mai Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$1.68 - $2.84 $17,088 - $28,888	-10,172 Reduced 3.98%	245,281 $618,000
Q1 2023 May 10, 2023	BUY	$1.21 - $2.86 $26,825 - $63,406	22,170 Added 9.5%	255,453 $508,000
Q4 2022 Feb 09, 2023	SELL	$1.06 - $58.5 $111,969 - $6.18 Million	-105,632 Reduced 31.17%	233,283 $268,000
Q3 2022 Nov 15, 2022	BUY	$1.59 - $60.0 $28,707 - $1.08 Million	18,055 Added 5.63%	338,915 $641,000
Q2 2022 Jul 19, 2022	BUY	$1.22 - $2.74 $391,449 - $879,156	320,860 New	320,860 $555,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $131M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.